/
Psychiatry
Attention Deficit Hyperactivity Disorder
14
Pipeline Programs↗
25
Active Trials↗
38
Companies Involved↗
Attention Deficit Hyperactivity Disorder is an emerging landscape with 14 programs across 38 companies. The most active players are Otsuka, Supernus Pharmaceuticals, Inc.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 1
No programs
Phase 2
No programs
Phase 34
Approved
No programs
Analysis
Trial Status
245
clinical trials
Completed184 · 75%
Unknown status18 · 7%
Recruiting15 · 6%
Terminated12 · 5%
Active, not recruiting6 · 2%
Withdrawn6 · 2%
Other4 · 2%
Clinical Trials
Trial Activity
245 trials
Effects of Transcranial Photobiomodulation on Cognition and Brain Metabolism in Adults With ADHD
Recruiting·—·Preclinical·NCT07203092·140 enrolled
Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation
Recruiting·—·Preclinical·NCT05802680·500 enrolled
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
Recruiting·—·Phase 4·NCT04421248·214 enrolled
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)